linjc16/ctgov huggingface dataset:
Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients

Study Overview
=================
Brief Summary
-----------------
Transurethral resection of the prostate (TURP) is a standard surgical treatment for benign prostatic hyperplasia (BPH). Non-conductive irrigation fluid is used to maintain good visibility of the operating field during resection of the prostate. Absorption of this hypotonic solution into the bloodstream can cause fluid overload and dilutional hyponatremia, resulting in adverse cardiovascular and central nervous system effects, transurethral resection (TUR) syndrome. BPH is common in elderly men above 60 years old. These aged people commonly have diastolic impairment by normal physiologic change without consistent symptom. This study aimed to evaluate the cardiac function focused mainly diastolic function during TURP with transthoracic echocardiography. Also, we will focus the effets of amount of irrgation fluid on left ventricular diastolic function in patients with pre-existing diastolic dysfunction.

Conditions
-----------------
BPH

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above 65years of age American Society of Anesthesiologists (ASA) Physical Status I, II, III. undergoing transurethral resection of the prostate(TURP) Exclusion Criteria: severe coagulopathy or bleeding disorder(platelet count<75000, PT INR >1.2) short stature (under 150 cm) underwent coronary artery bypass graft contraindications of regional anesthesia 

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>BPH patients with normal diastolic function | |
| Diastolic dysfunction<br>BPH patients with preoperative diastolic dysfunction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diastolic function by TTE |  | The participants will be followed for the duration of surgery (TURP), an expected average of 1 hour. |
Learning Curves for Airtraq Versus King Vision Laryngoscopes

Study Overview
=================
Brief Summary
-----------------
Several videolaryngoscopes have been developed but few have been compared in terms of their learning curves and efficacy. The aim of this study is to compare the learning curves of Airtraq versus King Vision in a group of residents trained in direct laryngoscopy. Four residents will perform, after a short training in manikin, 8 intubations with each device. The sequence of use of the devices will be randomized. Outcome measures will be duration of intubation attempt, glottic visualization and percentage of intubation success.

Official Title
-----------------
Learning Curves for Airtraq Versus King Vision Laryngoscopes

Conditions
-----------------
Intubation, Laryngoscopy

Intervention / Treatment
-----------------
* Device: Airtraq indirect laryngoscopy
* Device: King Vision indirect laryngoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status classification I-II. Elective surgery. General anesthesia required. Exclusion Criteria: Bronchoaspiration risk. Pharmacological allergies. Craniofacial anomalies. Body mass index > 30. Prior history of airway management complications. Presence of clinical signs predictive of difficult intubation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Airtraq indirect laryngoscopy<br>Intubation attempts using Airtraq device. | Device: Airtraq indirect laryngoscopy<br>* Attempt to intubation using the Airtraq device<br>|
| King Vision indirect laryngoscopy<br>Intubation attempts using King Vision device | Device: King Vision indirect laryngoscopy<br>* Attempt to intubation using the King Vision device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time for intubation | Time required from the insertion of the blade beyond the incisors until one complete wave pattern of capnography is monitored. | 60 seconds | 
| Glottic visualization | Scale of glottic visualization achieved | 60 seconds | 
| Intubation success | Percentage of intubation success | 60 seconds |
The Effect of Inelastic Compression System on Quality of Life in People With Chronic Venous Insufficiency

Study Overview
=================
Brief Summary
-----------------
The purpose of this protocol is to measure the effect of the use of an inelastic compression system (ICS) on quality of life (QOL) in patients with chronic venous insufficiency (CVI) who have demonstrated limited or no compliance with prescribed compression stockings or bandage wraps.

Official Title
-----------------
The Effect of Inelastic Compression System on Quality of Life in People With Chronic Venous Insufficiency

Conditions
-----------------
Chronic Venous Insufficiency

Intervention / Treatment
-----------------
* Device: Sigvaris Compreflex Inelastic Compression Wrap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is age 18 or older, able and willing to provide consent and agrees to comply with the study procedures Subject must have chronic venous insufficiency of stages C3, C4, or C5 according to the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification system Not compliant with their currently prescribed compression system Exclusion Criteria: Active malignancy other than non-melanoma skin cancer Study ulcer suspicious for cancer Subjects who are pregnant and/or breastfeeding In the opinion of the PI the subject cannot comply with study procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inelastic Compression System Group<br>Participants in this group will receive the inelastic compression wrap for daily use on their legs for 6 consecutive weeks. | Device: Sigvaris Compreflex Inelastic Compression Wrap<br>* Compreflex compression system using wraps to apply compression of 30-40 mmHg.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the Quality of Life as measured by CIVIQ-20 | Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20) consists of 20 multiple choice questions subdivided into four categories: psychology, pain, physical repercussions and social repercussions. The questionnaire has a total score ranging from 0 to 100 the lower score indicating greater quality of life. | Baseline to 6 weeks |
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Cerebral Palsy

Detailed Description
-----------------
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Cerebral Palsy (CP). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of CP. Patients with CP will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Official Title
-----------------
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Biological: AlloRx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Cerebral Palsy Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety Previous organ transplant Seizure disorder Hypersensitivity to sulfur
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group<br>Single intravenous infusion of 100 million cells | Biological: AlloRx<br>* cultured allogeneic adult umbilical cord derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: Gross Motor Function Measure (GMFM) | It will be completed for each follow up point | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CP, Cerebral Palsy, stem cell treatment
Phosphorous Magnetic Resonance Spectroscopy of Heart

Study Overview
=================
Brief Summary
-----------------
Heart needs constant supply of energy to continue working. Phosphorus magnetic resonance spectroscopy allows us to measure energy produced in the heart. The purpose of this study is to determine if the energy production is reduced in failing heart.

Detailed Description
-----------------
We will use non-invasive phosphorus magnetic resonance spectroscopy technique to measure creatine kinase (CK) flux in failing heart. The studies will be done on Siemens 3.0T human system. We will recruit subjects with LV dysfunction due to prior anterior wall myocardial infarction.

Official Title
-----------------
31P Magnetic Resonance Spectroscopy of Heart

Conditions
-----------------
Left Ventricular Dysfunction

Intervention / Treatment
-----------------
* Diagnostic Test: MR Spectroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals with left ventricular dysfunction Exclusion Criteria: Age < 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MR Spectroscopy Post-Heart Transplant<br>Patients post heart transplant getting heart biopsy | Diagnostic Test: MR Spectroscopy<br>* MR spectroscopy of myocardial<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| An MR Spectroscopy Showing Signal to Noise Ratio to Determine the Level of Heart Failure |  | 1-2 days |
PMCF Study on PEEK Suture Anchors for Hip Indications

Study Overview
=================
Brief Summary
-----------------
Post-market clinical follow-up on the PEEK Suture Anchors in the hip.

Official Title
-----------------
PMCF Study on PEEK Suture Anchors for Hip Indications

Conditions
-----------------
Soft Tissue to Bone Fixation

Intervention / Treatment
-----------------
* Device: PEEK Suture Anchors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have undergone hip joint repair using the study devices. Subjects aged 18 years and older at the time of surgery. Exclusion Criteria: Subjects who are < 12 months post-operative. Subject is entered in another investigational drug, biologic, or device study or has been treated with an investigational product within 30 days prior to surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PEEK Suture Anchors|Subjects who have undergone hip joint repair using PEEK Suture Anchors: Bioraptor Knotless Suture Anchor and SpeedLock Hip|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical success of the study devices in hip over a time period of 6 months after intervention | Clinical success is defined as the number of device failures in the hip | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical success of the study devices in hip over a time period of 12 months after intervention | Clinical success is defined as the number of device failures in the hip | 12 months | 
| Visual Analog Scale (VAS) - pain | 0 to 10 is the scoring range of pain for the joint that received treatment with the anchor | 12 months | 
| Range of Motion (ROM) | Flexion, extension, abduction, adduction, external/internal rotation will be captured in degrees based on physican's Standard of Care for this retrospective study. | 12 months |
Lung Ultrasound in Comparison With C.T in Covid-19

Study Overview
=================
Brief Summary
-----------------
investigate the diagnostic ability of thoracic ultrasound in suspicious COVID-19 infection and/or COVID-19 pneumonia. Also, to compare its findings to CT and follow up these findings.

Detailed Description
-----------------
ultrasound and C.T will be assessed in acute presentation of Covid 19 patients and then those patients will be reassessed again after 1 month by lung ultrasound and C.T and if ultrasound will show the same efficacy of diagnosis or not

Official Title
-----------------
Can Lung Ultrasound Play a Competitive Role With Computed Tomography in Diagnosis and Follow up of Covid-19 Patients?

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Radiation: ultrasound and C.T


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all cases of covid 19 patients Exclusion Criteria: all other causes of consolidation ,ground glass fibrosis or collapse findings of C.T and ultrasound

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| covid 19 in acute phase<br> | Radiation: ultrasound and C.T<br>* lung ultrasound in comparison to C.T<br>|
| covid 19 follow up<br> | Radiation: ultrasound and C.T<br>* lung ultrasound in comparison to C.T<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic ability of thoracic ultrasound for diagnosis and follow up of covid19 patients | compare lung ultrasound with C.T finding of covid 19 patients | after 1 month of acute presentation |
Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see whether patients undergoing ESWL, for upper tract urinary stones between 1.5-2.0cm, may be treated by expulsion therapy(Tamsulosin) instead of inserting ureteral stents .

Official Title
-----------------
Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Conditions
-----------------
Upper Tract Ureterolithiasis

Intervention / Treatment
-----------------
* Drug: Tamsulosin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients above 18 yrs of age. Single urolithiasis up to 2 cm. Kidney/ureters that haven't undergone previous ESWL or stent insertion. Normal renal function (creatinine below 100mmo1/1). Sterile urine culture. Normal CBC, blood electrolytes and coagulation studies. Radioopaque stones. Exclusion Criteria: More than one stone per kidney unit. Patients receiving steroids, NSAIDS, calcium channel blockers or alpha blockers on a regular basis. Anatomical anomalies or uromechanical obstruction. Single kidney. Cystinuria. Soldiers or pregnant women. Patients under 18 year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tamsulosin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stone status at 3 month . |  |  | 
| stone free |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
expulsion therapy, tamsulosin, ureterolithiasis, stents
Development of Field Test for Assessing the Human Anaerobic Capability

Study Overview
=================
Brief Summary
-----------------
A test of the validity of repeated sprint test (RST) 4x 30 meters, against the Wingate Anaerobic Test, which is the gold standard for measuring human anaerobic capacity. The following variables will be used: peak power, mean power and fatigue index. In addition, it will be tested against a 50 meter and a 200 meter shuttle run.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Repeated sprint test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Students Exclusion Criteria: Not healthy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br> | Behavioral: Repeated sprint test<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Human anaerobic capacity |  | Ten weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise test
Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the gene expression of the endometrium after an endometrial biopsy in fertile women using Next Generation Sequencing of total RNA.

Detailed Description
-----------------
An endometrial biopsy is done at cycle day LH+7 and repeated in the next cycle at cycle day LH+7. Tissue is analysed and compared for changes in gene expression profile using Seq RNA

Official Title
-----------------
Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Procedure: endometrial biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fertile women Age: 18-40 years BMI: 18-32 Regular menstrual cycle No use of hormonal contraceptives or IUD the last 3 months Exclusion Criteria: Patients in need of a interpreter Suspected intrauterine abnormalities Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: endometrial biopsy<br> | Procedure: endometrial biopsy<br> <br> * Other names: Pipelle de Cornier;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene Expression of the Endometrium after an endometrial biopsy | An endometrial biopsy is done at cycle day LH+7 and repeated in the next cycle at cycle day LH+7. Endometrial tissue is analysed for changes in gene expression profile of various chemokines and cytokines using RNA Sequencing technology | 1 month between each biopsy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility, Endometrium, Endometrial biopsy, Gene expression